Webinars » Accelerating Therapeutic Antibody Development: Discover Our Cutting-Edge CHO Expression Technology
Recent advances in recombinant antibody technology have facilitated the development of diverse antibody formats. However, achieving high expression and production levels remains a significant challenge. The CHO cell system is widely employed for recombinant antibody expression, with efficient expression and product quality influenced by factors such as genetic engineering of antibody sequences, optimization of expression vectors, and host cell characteristics.
As a leading provider of comprehensive recombinant protein and antibody services across various expression systems, GenScript is committed to partnering with scientists worldwide to accelerate scientific discovery. Our proprietary GenSmart™ Codon Optimization and newly launched TurboCHO™ expression platform ensure rapid delivery of high-yield, high-purity products in a flexible, cost-effective manner, minimizing time to market. Here, we explore how these innovations can advance your research and therapeutic development efforts.
Field Application Scientist, APAC region
Dr. Yerim Kwon joined GenScript in October 2023 as a Field Application Scientist, focusing on molecular biology, mRNA, and gene editing services. During her doctoral and postdoctoral research, she specialized in studying gene regulation pathways in response to environmental stress and RNA silencing. Her experience includes investigating RNA stability factors and post-translational regulation of RNA silencing pathways. Now, at GenScript, she applies her expertise to provide top-notch service to our clients.